Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
Tóm tắt
A long-acting factor VIII (FVIII) as a replacement therapy for hemophilia A would significantly improve treatment options for patients with hemophilia A. To develop a FVIII with an extended circulating half-life, but without a reduction in activity, we have engineered 23 FVIII variants with introduced surface-exposed cysteines to which a polyethylene glycol (PEG) polymer was specifically conjugated. Screening of variant expression level, PEGylation yield, and functional assay identified several conjugates retaining full in vitro coagulation activity and von Willebrand factor (VWF) binding.PEGylated FVIII variants exhibited improved pharmacokinetics in hemophilic mice and rabbits. In addition, pharmacokinetic studies in VWF knockout mice indicated that larger molecular weight PEG may substitute for VWF in protecting PEGylated FVIII from clearance in vivo. In bleeding models of hemophilic mice, PEGylated FVIII not only exhibited prolonged efficacy that is consistent with the improved pharmacokinetics but also showed efficacy in stopping acute bleeds comparable with that of unmodified rFVIII. In summary site-specifically PEGylated FVIII has the potential to be a long-acting prophylactic treatment while being fully efficacious for on-demand treatment for patients with hemophilia A.
Từ khóa
Tài liệu tham khảo
Lillicrap, 2008, Extending half-life in coagulation factors: where do we stand?, Thromb Res, 122, S2, 10.1016/S0049-3848(08)70027-6
Björkman, 2001, Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia., Clin Pharmacokinet, 40, 815, 10.2165/00003088-200140110-00003
Björkman, 2009, Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A., Eur J Clin Pharmacol, 65, 989, 10.1007/s00228-009-0676-x
Lenting, 1999, The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein., J Biol Chem, 274, 23734, 10.1074/jbc.274.34.23734
Saenko, 1999, Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism., J Biol Chem, 274, 37685, 10.1074/jbc.274.53.37685
Bovenschen, 2003, Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII., J Biol Chem, 278, 9370, 10.1074/jbc.M212053200
Bovenschen, 2005, LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo., Blood, 106, 906, 10.1182/blood-2004-11-4230
Sarafanov, 2001, Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein., J Biol Chem, 276, 11970, 10.1074/jbc.M008046200
Bovenschen, 2005, The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor., J Thromb Haemost, 3, 1257, 10.1111/j.1538-7836.2005.01389.x
Tuddenham, 1982, Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease., Br J Haematol, 52, 259, 10.1111/j.1365-2141.1982.tb03888.x
Schwarz, 2002, Recombinant von Willebrand factor-insight into structure and function through infusion studies in animals with severe von Willebrand disease., Semin Thromb Hemost, 28, 215, 10.1055/s-2002-27823
Weiss, 1977, Stabilization of factor VIII in plasma by the von Willebrand factor: studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease., J Clin Invest, 60, 390, 10.1172/JCI108788
Veronese, 2008, The impact of PEGylation on biological therapies., Biodrugs, 22, 315, 10.2165/00063030-200822050-00004
Bailon, 2009, PEG-modified biopharmaceuticals., Expert Opin Drug Deliv, 6, 1, 10.1517/17425240802650568
Fishburn, 2008, The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics., J Pharm Sci, 97, 4167, 10.1002/jps.21278
Roberts, 2002, Chemistry for peptide and protein PEGylation., Adv Drug Deliv Rev, 54, 459, 10.1016/S0169-409X(02)00022-4
Röstin, 2000, B-domain deleted recombinant coagulation factor VIII modified with monomethoxy polyethylene glycol., Bioconjug Chem, 11, 387, 10.1021/bc990137i
McMullen, 1995, Locations of disulfide bonds and free cysteines in the heavy and light chains of recombinant human factor VIII (antihemophilic factor A)., Protein Sci, 4, 740, 10.1002/pro.5560040413
Stoilova-McPhie, 2002, 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography., Blood, 99, 1215, 10.1182/blood.V99.4.1215
Ngo, 2008, Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex., Structure, 16, 597, 10.1016/j.str.2008.03.001
Shen, 2008, The tertiary structure and domain organization of coagulation factor VIII., Blood, 111, 1240, 10.1182/blood-2007-08-109918
Lind, 1995, Novel forms of B-domain-deleted recombinant factor VIII molecules., Eur J Biochem, 232, 19, 10.1111/j.1432-1033.1995.tb20776.x
Cho, 2003, Versatile expression system for rapid and stable production of recombinant proteins., Biotechnol Prog, 19, 229, 10.1021/bp0255964
Cho, 2002, Establishment of a human somatic hybrid cell line for recombinant protein production., J Biomed Sci, 9631
Bi, 1995, Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A., Nat Genet, 10, 119, 10.1038/ng0595-119
Denis, 1998, A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis., Proc Natl Acad Sci U S A, 95, 9524, 10.1073/pnas.95.16.9524
Pan, 2009, Enhanced efficacy of recombinant FVIII in non-covalent complex with PEGylated liposome in hemophilia A mice., Blood, 114, 2802, 10.1182/blood-2009-03-212423
Terraube, 2009, Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance., Haemophilia, 2009, 1
Ganz, 1991, Definition of the affinity of binding between human von Willebrand factor and coagulation factor VIII., Biochem Biophys Res Commun, 180, 231, 10.1016/S0006-291X(05)81281-1
Vlot, 1995, The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor., Blood, 85, 3150, 10.1182/blood.V85.11.3150.bloodjournal85113150
Sandberg, 2001, Structural and functional characteristics of the B-domain deleted recombinant factor VIII protein, r-VIII SQ., Thromb Haemost, 85, 93, 10.1055/s-0037-1612910
Ananyeva, 2004, Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives., Blood Coagul Fibrinolysis, 15, 109, 10.1097/00001721-200403000-00001
Shima, 2006, Characterization of factor VIII inhibitors., Int J Hematol, 83, 109, 10.1532/IJH97.05160
Healey, 1995, Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII., J Biol Chem, 270, 14505, 10.1074/jbc.270.24.14505
Lollar, 1994, Inhibition of human factor VIIIa by anti-A2 subunit antibodies., J Clin Invest, 93, 2497, 10.1172/JCI117259
Ansong, 2006, Epitope mapping factor VIII A2 domain by affinity-directed mass spectrometry: residues 497-510 and 584-593 comprise a discontinuous epitope for the monoclonal antibody R8B12., J Thromb Haemost, 4, 842, 10.1111/j.1538-7836.2006.01831.x
Ahmad, 2005, Role of the C2 domain of factor VIIIa in the assembly of factor-X activating complex on the platelet membrane., Biochemistry, 44, 13858, 10.1021/bi0511033
Gaberc-Porekar, 2008, Obstacles and pitfalls in the PEGylation of therapeutic proteins., Curr Opin Drug Discov Devel, 11, 242
Pan, 2006, Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist., J Biol Chem, 281, 12506, 10.1074/jbc.M600127200
Junutula, 2008, Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index., Nat Biotech, 26, 925, 10.1038/nbt.1480